
Most CMC leaders develop conventional antibodies. This one gets to help shape what comes next.
Cornerstone Search Group is partnering with a venture-backed, preclinical biotech to find its Vice President, CMC. The company is advancing a novel multivalent antibody-based platform for immuno-oncology toward the clinic. It is backed by top-tier life sciences investors and led by a CEO with a strong record of building and financing biotechs.
This is a seat on the executive team. You will own CMC strategy and also do the technical work, leading the program from process scale-up through GMP manufacturing, clinical supply and IND filing.
ABOUT THE OPPORTUNITY
The company's platform displays multiple antibody-derived binding domains on an engineered protein scaffold. This multivalent design lets it engage targets in ways conventional monoclonal and bispecific antibodies cannot. The lead program targets a co-stimulatory receptor that conventional antibodies have struggled to drug. Preclinical data have been presented at a major immuno-oncology meeting.
The company is moving from research stage to clinical stage. The VP, CMC will run the CMC work that gets the lead program into the clinic.
WHY THIS ROLE
Remote, United States (East coast preferred)
IN YOUR FIRST 12 TO 18 MONTHS, SUCCESS MEANS:
Required
Preferred
Cornerstone Search Group considers all inquiries, resume submissions, and any other personal information submitted to us as confidential information. This information will not be shared with any parties outside of Cornerstone Search Group without your prior permission.
#CMC #Biologics #Biotech #ProcessDevelopment #Antibodies #Bispecifics #ImmunoOncology #ExecutiveSearch #Hiring